U.S. Food and Drug Administration (FDA)
FDA Approves Durvalumab With Chemotherapy for Mismatch Repair–Deficient Primary Advanced or Recurrent Endometrial Cancer
On June 14, 2024, the U.S. Food and Drug Administration (FDA) approved durvalumab (Imfinzi®) with carboplatin plus paclitaxel followed by single-agent durvalumab for adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR).
June 14, 2024